Praziquantel efficacy, urinary and intestinal schistosomiasis reinfection - a systematic review.

ABSTRACT: Praziquantel (PZQ) has been extensively used as the drug of choice for the treatment of schistosomiasis on account of its safety and effectiveness against all major forms of schistosomiasis. However, low cure rate, reduced susceptibility of Schistosoma mansoni to PZQ and treatment failures in S. haematobium infections have been reported, raising concerns about its efficacy. Using the search terms, 'praziquantel efficacy, schistosomiasis, school children, reinfection' as well as defined inclusion criteria, and guided by the PRISMA guidelines, articles from 2001 to 2022 were selected from the PubMed and Google Scholar databases and reviewed to assess their importance to the research question. This review assessed the efficacy of PZQ against schistosomiasis and reinfectio

SUBMITTER: Aboagye IF 

PROVIDER: S-EPMC10498796 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature